Protagonist Therapeutics, Inc Operating Cash Flow
Protagonist Therapeutics, Inc (PTGX) reported Operating Cash Flow of $170.11 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- Protagonist Therapeutics, Inc net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $219.05M.
- Protagonist Therapeutics, Inc net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$48.94M, a 139.04% decline year-over-year.
- Protagonist Therapeutics, Inc net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$36.98M.
- Protagonist Therapeutics, Inc net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$1.94M.
- Protagonist Therapeutics, Inc net cash provided by (used in) operating activities for fiscal 2025 was $57.67M, a 68.68% decline from fiscal 2024.
- Protagonist Therapeutics, Inc net cash provided by (used in) operating activities for fiscal 2024 was $184.15M.
- Protagonist Therapeutics, Inc net cash provided by (used in) operating activities for fiscal 2023 was -$70.24M.
- Protagonist Therapeutics, Inc net cash provided by (used in) operating activities for fiscal 2022 was -$108.14M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $219.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $170.11M 10-Q · filed 2026-08-05 | $133.13M derived: sum of 3 quarters · filed 2026-08-05 | $131.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$48.94M 10-Q · filed 2026-05-05 | -$85.92M derived: sum of 2 quarters · filed 2026-05-05 | -$87.86M derived: sum of 3 quarters · filed 2026-05-05 | -$116.64M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$36.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$38.91M derived: sum of 2 quarters · filed 2026-02-25 | -$67.69M derived: sum of 3 quarters · filed 2026-08-05 | $57.67M 10-K · filed 2026-02-25 |
| 2025-09-30 | -$1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$30.72M derived: sum of 2 quarters · filed 2026-08-05 | $94.65M 10-Q · filed 2025-11-06 | $65.47M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$28.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $96.58M 10-Q · filed 2026-08-05 | $67.41M derived: sum of 3 quarters · filed 2026-08-05 | $39.54M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $125.36M 10-Q · filed 2026-05-05 | $96.19M derived: sum of 2 quarters · filed 2026-05-05 | $68.32M derived: sum of 3 quarters · filed 2026-05-05 | $336.94M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$29.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$57.04M derived: sum of 2 quarters · filed 2026-02-25 | $211.58M derived: sum of 3 quarters · filed 2026-02-25 | $184.15M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$27.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $240.76M derived: sum of 2 quarters · filed 2025-11-06 | $213.33M 10-Q · filed 2025-11-06 | $230.29M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $268.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $241.19M 10-Q · filed 2025-08-06 | $258.15M derived: sum of 3 quarters · filed 2026-02-25 | $231.54M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$27.43M 10-Q · filed 2025-05-06 | -$10.47M derived: sum of 2 quarters · filed 2026-02-25 | -$37.08M derived: sum of 3 quarters · filed 2026-02-25 | -$63.32M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $16.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$9.65M derived: sum of 2 quarters · filed 2026-02-25 | -$35.89M derived: sum of 3 quarters · filed 2026-02-25 | -$70.24M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$26.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$52.85M derived: sum of 2 quarters · filed 2024-11-07 | -$87.20M 10-Q · filed 2024-11-07 | -$118.83M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | -$26.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$60.59M 10-Q · filed 2024-08-06 | -$92.22M derived: sum of 3 quarters · filed 2025-02-21 | -$117.42M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | -$34.35M 10-Q · filed 2024-05-07 | -$65.98M derived: sum of 2 quarters · filed 2025-02-21 | -$91.18M derived: sum of 3 quarters · filed 2025-02-21 | -$104.82M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | -$31.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$56.84M derived: sum of 2 quarters · filed 2025-02-21 | -$70.47M derived: sum of 3 quarters · filed 2025-02-21 | -$108.14M 10-K · filed 2025-02-21 |
| 2022-09-30 | -$25.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$38.84M derived: sum of 2 quarters · filed 2023-11-02 | -$76.50M 10-Q · filed 2023-11-02 | -$103.44M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$13.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$51.30M 10-Q · filed 2023-08-03 | -$78.24M derived: sum of 3 quarters · filed 2024-02-27 | -$106.71M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$37.67M 10-Q · filed 2023-05-04 | -$64.61M derived: sum of 2 quarters · filed 2024-02-27 | -$93.08M derived: sum of 3 quarters · filed 2024-02-27 | -$116.78M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$26.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$55.41M derived: sum of 2 quarters · filed 2024-02-27 | -$79.11M derived: sum of 3 quarters · filed 2024-02-27 | -$107.86M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$28.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$52.17M derived: sum of 2 quarters · filed 2022-11-08 | -$80.93M 10-Q · filed 2022-11-08 | -$99.79M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | -$23.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$52.46M 10-Q · filed 2022-08-04 | -$71.32M derived: sum of 3 quarters · filed 2023-03-15 | -$87.61M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | -$28.76M 10-Q · filed 2022-05-05 | -$47.62M derived: sum of 2 quarters · filed 2023-03-15 | -$63.91M derived: sum of 3 quarters · filed 2023-03-15 | -$85.39M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | -$18.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$35.15M derived: sum of 2 quarters · filed 2023-03-15 | -$56.64M derived: sum of 3 quarters · filed 2023-03-15 | -$72.48M 10-K · filed 2023-03-15 |
| 2020-09-30 | -$16.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$37.77M derived: sum of 2 quarters · filed 2021-11-03 | -$53.62M 10-Q · filed 2021-11-03 | -$67.91M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$21.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$37.33M 10-Q · filed 2021-08-04 | -$51.62M derived: sum of 3 quarters · filed 2022-02-28 | -$65.86M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$15.85M 10-Q · filed 2021-05-04 | -$30.14M derived: sum of 2 quarters · filed 2022-02-28 | -$44.38M derived: sum of 3 quarters · filed 2022-02-28 | -$40.71M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$14.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$28.54M derived: sum of 2 quarters · filed 2022-02-28 | -$24.86M derived: sum of 3 quarters · filed 2022-02-28 | -$41.53M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$14.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$10.58M derived: sum of 2 quarters · filed 2020-11-04 | -$27.24M 10-Q · filed 2020-11-04 | -$37.37M derived: sum of 4 quarters · filed 2021-03-10 |
| 2019-06-30 | $3.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$12.99M 10-Q · filed 2020-08-06 | -$23.13M derived: sum of 3 quarters · filed 2021-03-10 | -$32.40M derived: sum of 4 quarters · filed 2021-03-10 |
| 2019-03-31 | -$16.66M 10-Q · filed 2020-05-07 | -$26.80M derived: sum of 2 quarters · filed 2021-03-10 | -$36.07M derived: sum of 3 quarters · filed 2021-03-10 | -$51.47M derived: sum of 4 quarters · filed 2021-03-10 |
| 2018-12-31 | -$10.13M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | -$19.41M derived: sum of 2 quarters · filed 2021-03-10 | -$34.81M derived: sum of 3 quarters · filed 2021-03-10 | -$49.95M 10-K · filed 2021-03-10 |
| 2018-09-30 | -$9.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$24.67M derived: sum of 2 quarters · filed 2019-11-06 | -$39.81M 10-Q · filed 2019-11-06 | -$53.96M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-06-30 | -$15.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$30.54M 10-Q · filed 2019-08-07 | -$44.69M derived: sum of 3 quarters · filed 2020-03-10 | -$3.98M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-03-31 | -$15.14M 10-Q · filed 2019-05-08 | -$29.29M derived: sum of 2 quarters · filed 2020-03-10 | $11.42M derived: sum of 3 quarters · filed 2020-03-10 | -$910.00K derived: sum of 4 quarters · filed 2020-03-10 |
| 2017-12-31 | -$14.15M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $26.55M derived: sum of 2 quarters · filed 2020-03-10 | $14.23M derived: sum of 3 quarters · filed 2020-03-10 | $3.87M 10-K · filed 2020-03-10 |
| 2017-09-30 | $40.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $28.38M derived: sum of 2 quarters · filed 2018-11-06 | $18.02M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | -$12.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$22.68M 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | -$10.36M 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | -$29.97M 10-K · filed 2019-03-12 | |||
| 2015-12-31 | -$14.38M 10-K · filed 2018-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |